Rio de Janeiro, Friday 13 April 2018 11.00 BRT
Deprexis has launched in Brazil! Deprexis is a fully-automated therapy for individuals suffering from depressive disorders.
According to the World Health Organization, Brazil has one of the highest numbers of people suffering from depression and anxiety. GAIA AG developed deprexis in 2007 to help mitigate the huge global disease burden that is further compounded by poor access to adequate clinical intervention.
This market launch means desiring patients in Brazil can now get therapy in their mother tongue; Brazilian Portuguese. Currently, deprexis is available in 9 languages. This includes English, German, Spanish, Greek, French, Italian, European Portuguese, and Swedish.
In 2016, GAIA licensed deprexis to the global pharmaceutical company, Servier. The remarkable partnership has facilitated the clinical application of deprexis internationally; ensuring that many who suffer from depression can access this clinical and cost-effective treatment in their markets.